CINJ 050705: OAM4224g: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-MET, Administered Intravenously in Patients with Locally Advanced or Metastatic Solid Tumours.

Trial Profile

CINJ 050705: OAM4224g: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-MET, Administered Intravenously in Patients with Locally Advanced or Metastatic Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2017

At a glance

  • Drugs Onartuzumab (Primary) ; Bevacizumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 02 Apr 2011 Final results presented at AACR 2011.
    • 18 Feb 2010 Planned initiation date (1 Aug 2007), actual number of patients (44), lead trial investigator (Patel P) and investigational drug (bevacizumab) identified as reported by ClinicalTrials.gov record.
    • 18 Feb 2010 New source identified and integrated (ClinicalTrials.gov record; NCT01068977)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top